The nation of Zimbabwe has rejected a significant US health deal valued at 367 million US dollars (£272m) spanning five years over Washington's request for sensitive biological samples.
This move became public after a government memo from December was leaked, indicating that President Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesperson has since clarified that the US was demanding access to biological samples for scientific study and commercial gain while was unwilling to share the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more negotiations to find a agreement agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This development follows a comparable case in Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral deals to enhance openness and responsibility.
Based on reports, 16 African countries have to date signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," he stated.
"Effectively, our country would supply the basic resources for medical research with no assurance that the end products would be accessible to our population should a new health crisis arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending systems previously established through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is designed to guarantee that when a nation contributes its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how future co-operation could be arranged in a way that honours the independence and dignity of each country."
Medical Community Response
Medical experts stated it acknowledged the government's concerns, but suggested that talks should continue since a large portion of the country's Aids initiatives were funded by external financing.
"If specific concerns exist, such as those relating to information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group commented.
The situation emphasises the continuing debate between receiving crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.